Harvard Bioscience (NASDAQ:HBIO) Stock Crosses Below Two Hundred Day Moving Average – What’s Next?

Harvard Bioscience, Inc. (NASDAQ:HBIO)’s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.05 and traded as low as $6.01. Harvard Bioscience shares last traded at $6.01, with a volume of 10,605 shares changing hands.

Analyst Upgrades and Downgrades

HBIO has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Friday, March 27th. Benchmark reduced their price objective on shares of Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating for the company in a research note on Friday, March 13th. New Street Research set a $6.00 price objective on shares of Harvard Bioscience in a research note on Friday, March 13th. Finally, Wall Street Zen lowered shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, March 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Harvard Bioscience has a consensus rating of “Hold” and a consensus price target of $6.00.

Harvard Bioscience Stock Performance

The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.06 and a current ratio of 1.99. The stock has a market cap of $27.11 million, a P/E ratio of -2.77 and a beta of 1.53. The firm’s 50 day moving average is $5.85 and its 200 day moving average is $6.05.

Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings data on Tuesday, May 12th. The medical instruments supplier reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.29. The firm had revenue of $20.76 million during the quarter, compared to analyst estimates of $21.20 million. Harvard Bioscience had a negative net margin of 11.44% and a negative return on equity of 25.78%.

Insider Buying and Selling at Harvard Bioscience

In related news, Director William Snider purchased 12,525 shares of the business’s stock in a transaction on Monday, March 16th. The shares were acquired at an average price of $4.99 per share, for a total transaction of $62,499.75. Following the purchase, the director owned 23,525 shares of the company’s stock, valued at $117,389.75. This trade represents a 113.86% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Stephen J. Denelsky purchased 10,000 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were bought at an average price of $4.87 per share, for a total transaction of $48,700.00. Following the purchase, the director directly owned 21,000 shares in the company, valued at $102,270. This represents a 90.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have purchased 36,000 shares of company stock worth $177,354. 20.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Nano Cap New Millennium Growth Fund L P acquired a new position in Harvard Bioscience during the 4th quarter valued at approximately $401,000. Gamco Investors INC. ET AL acquired a new position in Harvard Bioscience during the 4th quarter valued at approximately $38,000. Williams & Novak LLC increased its stake in Harvard Bioscience by 26.6% during the 4th quarter. Williams & Novak LLC now owns 348,800 shares of the medical instruments supplier’s stock valued at $233,000 after purchasing an additional 73,300 shares in the last quarter. Weber Capital Management LLC ADV acquired a new position in Harvard Bioscience during the 4th quarter valued at approximately $2,140,000. Finally, XTX Topco Ltd acquired a new position in Harvard Bioscience during the 4th quarter valued at approximately $26,000. Institutional investors and hedge funds own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.